Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria - Report of a Meeting Held 16-18 December 2003 Geneva
(2003; 199 pages) View the PDF document
Table of Contents
Open this folder and view contentsSummary: Observations and some ways forward
Open this folder and view contentsWelcome
Open this folder and view contentsFixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective
Open this folder and view contentsProduct costs of fixed-dose combination tablets in comparison with separate dispensing and or co-blistering of antituberculosis drugs
Open this folder and view contentsFixed-dose combinations: artemisinin-based combination therapies for malaria treatment
Open this folder and view contentsDeveloping combinations of drugs for malaria examination of critical issues and lessons learnt
Close this folderSafety and long-term effectiveness of generic fixed-dose formulations of nevirapine-based HAART amongst antiretroviral-naïve HIV-infected patients in India
View the documentAbstract
View the documentIntroduction
View the documentMethods
View the documentResults
View the documentDiscussion
View the documentImmunological improvement
View the documentViral load
View the documentClinical findings
View the documentConclusions
View the documentReferences
Open this folder and view contentsEffect of introduction of fixed-dose combinations on the drug supply chain: experiences from the field
Open this folder and view contentsEffect of fixed-dose combination (FDC) medications on adherence and treatment outcomes
Open this folder and view contentsEffect of fixed-dose combination (FDC) drugs on development of clinical antimicrobial resistance: a review paper
Open this folder and view contentsFixed-dose combination (FDC) drugs availability and use as a global public health necessity: intellectual property and other legal issues
Open this folder and view contentsPharmaceutical development and quality assurance of FDCs
View the documentAnnotated agenda
View the documentList of participants
 

Immunological improvement

The magnitude of the improvement of the mean CD4 cell count seen in this study is one of the largest reported for this regimen in literature [14]. One of the reasons may be that patients initiated HAART at lower CD4 counts than in most other studies. There was a substantial improvement in the CD4 counts initially (after 3-6 months) which was subsequently sustained. The initial improvement is postulated to be due to redistribution of memory CD4 cells from the lymph nodes into the blood and later improvement because of the production of naïve CD4 cells. Although a significant proportion of patients started therapy at advanced stages of HIV infection there was still a remarkable improvement in CD4 counts indicating the potency of this regimen and these formulations.

to previous section to next section
 

Last updated: May 3, 2013